Opportunities Outweigh Challenges For Postmarketing Studies – BMS Exec
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Both challenges and opportunities exist for conducting post-marketing safety studies for drugs, but the opportunities far outweigh the challenges, Bristol-Myers Squibb VP Medical Safety Amrit Ray said Oct. 30 at Shanghai Institute for Food and Drug Safety's 2008 Drug Safety and Public Policy International Conference
You may also be interested in...
Singapore’s Health System Holds Promise To Develop Drug Monitoring Devices
With Singapore’s biomedical infrastructure and small population, it is an ideal place to test devices that could redefine the way therapies are developed and monitored.
China Enhances Dope Management And ADR Systems
SHANGHAI - China will forbid pharmaceutical and chemical companies in China from manufacturing, selling, trading, exporting and importing any anabolic agents without the government approval, and China's State FDA will improve the adverse drug reaction report system, SFDA said at a July 8 press conference
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).